Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection
- PMID: 22990849
- DOI: 10.1093/cid/cis809
Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection
Abstract
Background: Fecal microbiota transplantation (FMT), a safe, effective alternative therapy for recurrent Clostridium difficile infection (CDI), is infrequently used, in part because of an assumption that patients are unwilling to consider FMT because of its unappealing nature.
Methods: Through a structured survey, including hypothetical case scenarios, we assessed patient perceptions of the aesthetics of FMT and their willingness to consider it as a treatment option, when presented with scenarios involving recurrent CDI.
Results: Four hundred surveys were distributed; 192 (48%) were returned complete. Seventy percent of respondents were female; 59% were >49 years of age. When provided efficacy data only, 162 respondents (85%) chose to receive FMT, and 29 (15%) chose antibiotics alone. When aware of the fecal nature of FMT, 16 respondents changed their choice from FMT to antibiotics alone, but there was no significant change in the total number choosing FMT (154 [81%]; P = .15). More respondents chose FMT if offered as a pill (90%; P = .002) or if their physician recommended it (94%; P < .001). Respondents rated all aspects of FMT at least "somewhat unappealing," selecting "the need to handle stool" and "receiving FMT by nasogastric tube" as most unappealing. Women rated all aspects of FMT more unappealing; older respondents rated all aspects less unappealing. Most respondents preferred to receive FMT in the hospital (48%) or physician's office (39%); 77% were willing to pay out-of-pocket for FMT.
Conclusions: Patients recognize the inherently unappealing nature of FMT, but they are nonetheless open to considering it as a treatment alternative for recurrent CDI, especially when recommended by a physician.
Comment in
-
Editorial commentary: fecal microbiota transplantation: patient and physician attitudes.Clin Infect Dis. 2012 Dec;55(12):1659-60. doi: 10.1093/cid/cis812. Epub 2012 Sep 18. Clin Infect Dis. 2012. PMID: 22990845 No abstract available.
Similar articles
-
Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection.Am J Gastroenterol. 2012 Jul;107(7):1079-87. doi: 10.1038/ajg.2012.60. Epub 2012 Mar 27. Am J Gastroenterol. 2012. PMID: 22450732
-
Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results.J Clin Gastroenterol. 2012 Feb;46(2):145-9. doi: 10.1097/MCG.0b013e318234570b. J Clin Gastroenterol. 2012. PMID: 22157239
-
Fecal microbiota transplant for recurrent Clostridium difficile infection: Mayo Clinic in Arizona experience.Mayo Clin Proc. 2013 Aug;88(8):799-805. doi: 10.1016/j.mayocp.2013.04.022. Mayo Clin Proc. 2013. PMID: 23910407
-
Fecal microbiota transplantation for recurrent clostridium difficile infection.J Clin Gastroenterol. 2011 Nov;45 Suppl:S159-67. doi: 10.1097/MCG.0b013e318222e603. J Clin Gastroenterol. 2011. PMID: 21992957 Review.
-
An overview of fecal microbiota transplantation: techniques, indications, and outcomes.Gastrointest Endosc. 2013 Aug;78(2):240-9. doi: 10.1016/j.gie.2013.03.1329. Epub 2013 May 2. Gastrointest Endosc. 2013. PMID: 23642791 Review. No abstract available.
Cited by
-
Recurrent Clostridioides difficile Infection and Outcome of Fecal Microbiota Transplantation Use: A Population-Based Assessment.Open Forum Infect Dis. 2024 Jun 15;11(7):ofae309. doi: 10.1093/ofid/ofae309. eCollection 2024 Jul. Open Forum Infect Dis. 2024. PMID: 38975247 Free PMC article.
-
Protective effects of fecal microbiota transplantation against ischemic stroke and other neurological disorders: an update.Front Immunol. 2024 Feb 21;15:1324018. doi: 10.3389/fimmu.2024.1324018. eCollection 2024. Front Immunol. 2024. PMID: 38449863 Free PMC article. Review.
-
Patient Experiences with Clostridioides difficile Infection and Its Treatment: A Systematic Literature Review.Infect Dis Ther. 2023 Jul;12(7):1775-1795. doi: 10.1007/s40121-023-00833-x. Epub 2023 Jul 3. Infect Dis Ther. 2023. PMID: 37395984 Free PMC article. Review.
-
Modulation of the Gut Microbiota to Control Antimicrobial Resistance (AMR)-A Narrative Review with a Focus on Faecal Microbiota Transplantation (FMT).Infect Dis Rep. 2023 May 9;15(3):238-254. doi: 10.3390/idr15030025. Infect Dis Rep. 2023. PMID: 37218816 Free PMC article. Review.
-
Fecal Microbiota Transplantation in Reducing Uremic Toxins Accumulation in Kidney Disease: Current Understanding and Future Perspectives.Toxins (Basel). 2023 Jan 31;15(2):115. doi: 10.3390/toxins15020115. Toxins (Basel). 2023. PMID: 36828429 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
